Kelbel C, Stumpf B, Schmidt W, Wetzel E, Lorenz J
Kreiskrankenhaus Lüdenscheid, Akademisches Lehrkrankenhaus, Universität Bonn.
Pneumologie. 1995 Dec;49(12):684-8.
We measured serum levels of adenosine-deaminase (ADA) in 44 tuberculosis patients, 70 patients with lung cancer pre treatment, and 130 normal blood donors. Increased ADA levels were found in 64.4% of the tuberculosis patients, in 95.2% in the case of bacillary tuberculosis, but only in 2.8% in the tumor patients. ADA serum levels were statistically significantly increased in tuberculosis patients when compared to lung cancer patients and controls and did not differ between controls and the tumor group. We conclude that serum ADA is a selective marker of immune stimulation in tuberculosis but not in lung cancer. Serum levels positively correlated to the disease extent in tuberculosis of immunocompetent patients. This marker deserves further investigation with respect to its clinical significance.
我们检测了44例肺结核患者、70例肺癌患者治疗前及130名正常献血者的血清腺苷脱氨酶（ADA）水平。64.4%的肺结核患者ADA水平升高，菌阳肺结核患者中这一比例为95.2%，而肿瘤患者中仅为2.8%。与肺癌患者和对照组相比，肺结核患者的血清ADA水平在统计学上显著升高，对照组与肿瘤组之间无差异。我们得出结论，血清ADA是肺结核免疫刺激的选择性标志物，而非肺癌的标志物。免疫功能正常的肺结核患者血清水平与疾病严重程度呈正相关。就其临床意义而言，该标志物值得进一步研究。
